Dalbavancin to prevent infections in children with high-risk leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 25 years old or younger.
- You are being treated for acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL) at St. Jude.
- Your treatment is expected to cause low white blood cell counts for more than 7 days.
- You can receive care at St. Jude for at least 56 days after joining the study.
- If you are female and 9 or older, you must have a negative pregnancy test before starting the study drug.
- You do not have allergies to certain antibiotics (vancomycin, dalbavancin, teicoplanin, levofloxacin, or ciprofloxacin) and have no other conditions that make participation unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a preventive antibiotic during chemotherapy can lower the risk of infections in people with certain blood cancers. It may help reduce hospital stays and improve treatment outcomes.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.